GRI Bio Inc. (NASDAQ:GRI) — Market Cap & Net Worth
Market Cap & Net Worth: GRI Bio Inc. (GRI)
GRI Bio Inc. (NASDAQ:GRI) has a market capitalization of $3.35 Million ($3.35 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29385 globally and #6000 in its home market, demonstrating a -5.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRI Bio Inc.'s stock price $1.89 by its total outstanding shares 1770838 (1.77 Million). Also see GRI current and non-current assets for a full breakdown of the balance sheet.
GRI Bio Inc. Market Cap History: 2021 to 2026
GRI Bio Inc.'s market capitalization history from 2021 to 2026. Data shows change from $28.91 Billion to $3.35 Million (-81.01% CAGR). Also see GRI Bio Inc. (GRI) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
GRI Bio Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #856 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #2736 of 3165 |
Weight: GRI Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GRI Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRI Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GRI Bio Inc. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
GRI Bio Inc.'s market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $62.04 Million | $21.77 Million | -$13.04 Million | 2.85x | N/A |
| 2024 | $1.47 Million | $22.54 Million | -$8.21 Million | 0.07x | N/A |
Competitor Companies of GRI by Market Capitalization
Companies near GRI Bio Inc. in the global market cap rankings as of September 17, 2026. Review GRI intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GRI Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
GRI Bio Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, GRI Bio Inc.'s market cap moved from $28.91 Billion to $ 3.35 Million, with a yearly change of -81.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.35 Million | +665.80% |
| 2025 | $437.04K | -70.21% |
| 2024 | $1.47 Million | -97.64% |
| 2023 | $62.04 Million | -95.57% |
| 2022 | $1.40 Billion | -95.15% |
| 2021 | $28.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of GRI Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.35 Million USD |
| MoneyControl | $3.35 Million USD |
| MarketWatch | $3.35 Million USD |
| marketcap.company | $3.35 Million USD |
| Reuters | $3.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more